

May 26, 2025

| | |
|--|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|--|--|

Dear Sir / Madam,

Sub: Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2025.

We enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2025.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi Har, Ameerpet, Hyderabad -500038, Telangana., India Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Hyderabad, India, May 26th, 2025: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended March 31, 2025.

Aurobindo Pharma Limited Q4FY25 and FY25 Consolidated Financial Results

| Amount (INR Cr) | Q4 FY25 | Q4 FY24 | %Change YoY | Q3 FY25 | %Change QoQ | FY25 | FY24 | %Change YoY |
|--|------------|------------|----------------|------------|----------------|--------|--------|----------------|
| Revenue from Operations | 8,382 | 7,580 | 10.6% | 7,979 | 5.1% | 31,724 | 29,002 | 9.4% |
| EBITDA before R&D | 2,202 | 2,056 | 7.1% | 2,056 | 7.1% | 8,148 | 7,236 | 12.6% |
| EBITDA margin before R&D | 26.3% | 27.1% | -85 bps | 25.8% | 51 bps | 25.7% | 24.9% | 73 bps |
| EBITDA before Forex and Other Income | 1,792 | 1,687 | 6.2% | 1,628 | 10.1% | 6,605 | 5,843 | 13.0% |
| EBITDA Margin (%) | 21.4% | 22.3% | -88 bps | 20.4% | 98 bps | 20.8% | 20.1% | 67 bps |
| PBT before share of P/L of JV, Forex, and Exceptional items | 1,356 | 1,379 | -1.7% | 1,248 | 8.6% | 5,120 | 4,550 | 12.5% |
| Net Profit for the period | 903 | 907 | -0.5% | 846 | 6.7% | 3,484 | 3,169 | 9.9% |

Key Highlights of Q4FY25

- Revenue from Operations increased by 10.6% YoY to INR 8,382 Cr with growth across the businesses
- US formulations revenue increased by 13.5% YoY to INR 4,072 Cr (USD 470 million)
- Europe formulations revenue increased by 17.2% YoY to INR 2,147 Cr (EUR 236 million)
- Growth Markets revenue decreased by 7.8% YoY to INR 786 Cr (USD 91 million)
- ARV revenue increased by 29.4% YoY to INR 308 Cr (USD 36 million)
- API revenue increased by 5.0% YoY to INR 1,069 Cr (USD 124 million)
- EBITDA before R&D stood at INR 2,202 crores with a margin of 26.3%
- EBITDA before Forex and Other Income stood at INR 1,792 Cr; EBITDA margin at 21.4%
- Research & Development (R&D including depreciation) spend was INR 423 Cr, 5.0% of revenues
- Received final approval for 5 ANDAs (including 2 ANDA previously tentatively approved, now receiving the final approval) from the USFDA
- Net Profit for the period stood at INR 903 Cr
- Basic & Diluted EPS stood at INR 15.56 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio. Our European operations continue to perform exceptionally well, moving steadily towards the \$1 billion revenue milestone. Backed by our ongoing capacity enhancements we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders."



Operational Performance (Consolidated)

| ₹ Cr | Q4FY25 | Q4FY24 | Y-o-Y (%) | Q3FY25 | Q-o-Q (%) | FY25 | FY24 | Y-o-Y (%) |
|--|--------------|--------------|--------------|--------------|-------------|---------------|---------------|--------------|
| USA | 4,072 | 3,588 | 13.5% | 3,671 | 10.9% | 14,816 | 13,867 | 6.8% |
| Europe | 2,147 | 1,832 | 17.2% | 2,121 | 1.2% | 8,356 | 7,166 | 16.6% |
| Growth Markets | 786 | 852 | -7.8% | 873 | -10.0% | 3,180 | 2,517 | 26.3% |
| ARV | 308 | 238 | 29.4% | 307 | 0.4% | 1,037 | 868 | 19.4% |
| Total Formulations | 7,313 | 6,510 | 12.3% | 6,973 | 4.9% | 27,388 | 24,419 | 12.2% |
| Beta-lactam | 789 | 698 | 13.1% | 722 | 9.3% | 3,139 | 2,970 | 5.7% |
| Non Beta-lactam | 280 | 321 | -12.6% | 284 | -1.3% | 1,184 | 1,270 | -6.8% |
| Total API | 1,069 | 1,019 | 5.0% | 1,006 | 6.3% | 4,323 | 4,241 | 1.9% |
| Consolidated Sales (Ex-Puerto Rico) | 8,382 | 7,529 | 11.3% | 7,979 | 5.1% | 31,711 | 28,660 | 10.6% |
| Puerto Rico | - | 51 | - | - | - | 13 | 342 | - |
| Revenue from operations | 8,382 | 7,580 | 10.6% | 7,979 | 5.1% | 31,724 | 29,002 | 9.4% |

*Includes domestic formulation sales of INR 56 Cr in Q4FY25



Q4FY25: Consolidated Revenue Breakup

Q4FY25



FY25: Consolidated Revenue Breakup

FY25



Q4FY25 Performance

Formulations revenue increased by 12.3% YoY to INR 7,313 Cr.

US Formulations

- US revenue increased by 13.5% YoY to INR 4,072 Cr mainly driven by volume growth, stable pricing environment and new product launches; and accounted for 48.6% of consolidated revenue
- In USD terms, revenue increased by 8.8% YoY to USD 470 million
- Filed 9 ANDAs with USFDA during the quarter
- Received final approval for 5 ANDAs (of which 2 ANDAs had earlier received tentative approval, now received final approval) during the quarter
- As on 31st March 2025, on a cumulative basis, the company has filed 861 ANDAs with USFDA and received 690 final approvals and 29 tentative approvals
- The company has launched 5 products during the quarter

Europe Formulations

- Europe revenue increased by 17.2% YoY to INR 2,147 Cr driven by strong performance across all key markets; and accounted for 25.6% of consolidated revenue
- In Euro terms, revenue increased by 16.0% YoY to EUR 236 million

Growth Markets Formulations

- Growth Markets formulations revenue decreased by 7.8% YoY to INR 786 Cr impacted by moderated performance in a few markets; and accounted for 9.4% of consolidated revenue
- In USD terms, revenue decreased by 11.7% YoY to USD 91 million
- Domestic formulation sales for the quarter stood at INR 56 Cr

ARV Formulations

- ARV business revenue increased by 29.4% YoY to INR 308 Cr accounting for 3.7% of consolidated revenue
- In USD terms, revenue increased by 24.1% YoY to USD 36 million

Active Pharmaceutical Ingredients (API)

- API revenues increased by 5.0% Y-o-Y to INR 1,069 Cr contributing to 12.8% of consolidated revenue
- In USD terms, revenue increased by 0.7% to USD 124 million

Global Regulatory Filings

| Details | Q4FY25 | Cumulative Filings as on 31 st Mar 2025 |
|---|--------|---|
| US ANDAs (including filings from Aurobindo USA) | 9 | 861 |
| US DMFs (including filings from Eugia and Auro Peptides) | 12 | 309 |
| Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada) | 90 | 4,625 |
| API filings in other key regulated markets (incl. multiple registrations) | 47 | 3,991 |

Final USFDA Approvals Received in Q4FY25

Received by Aurobindo Pharma Limited

| # | Product | Strength | Therapy area |
|---|--|------------------------|------------------------|
| 1 | Tretinoin Gel USP | 0.01% | Anti-Infective |
| 2 | Tretinoin Gel USP | 0.025% | Anti-Infective |
| 3 | Nystatin Cream USP | 100,000 units per gram | Anti-Fungal Agent |
| 4 | Azelastine Hydrochloride Nasal Spray (OTC)* | 205.5mcg | Anti-Histamine |
| 5 | Pantoprazole Sodium for Delayed-Release Oral Suspension* | 40mg | Gastrointestinal drugs |

* ANDAs previously tentatively approved has now received final approval in Q4 FY25

Q4FY25 Earnings Call Details

The company will host earnings call at **8.30 AM IST on 27th May 2025**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <http://bit.ly/44M2CK4>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com